Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes

Clinical Endocrinology

Volumn 71, Issue 1, 2009, Pages 27-32

  Von Eynatten, M ^a   Liu, D ^a,b   Bluemm, A ^c   Schuster, T ^d   Baumann, M ^a   Lutz, J ^a   Heemann, U ^a   Dugi, K A ^e   Nawroth, P P ^e   Bierhaus, A ^e   Humpert, P M ^e  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; ISOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WESTERN BLOTTING;

ADIPONECTIN; ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PROTEIN MULTIMERIZATION; PYRROLES;

EID: 66949129931     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03412.x     Document Type: Article

References (26)

1. Pischon, T., Girman, C.J., Hotamisligil, G.S. et al. (2004) Plasma adiponectin levels and risk of myocardial infarction in men. Journal of the American Medical Association, 14, 1730 1737. (Pubitemid 38489895)
2. Koenig, W., Khuseyinova, N., Baumert, J. et al. (2006) Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. Journal of the American College of Cardiology, 48, 1369 1377. (Pubitemid 44436825)
3. Lawlor, D.A., Davey Smith, G., Ebrahim, S. et al. (2005) Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. Journal of Clinical Endocrinology and Metabolism, 90, 5677 5683. (Pubitemid 41415475)
4. Sattar, N., Watt, P., Cherry, L. et al. (2008) High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study. Journal of Clinical Endocrinology and Metabolism, 93, 1846 1849. (Pubitemid 351656528)
5. von Eynatten, M., Humpert, P.M., Bluemm, A. et al. (2008) High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis, 199, 123 128. (Pubitemid 351842696)
6. von Eynatten, M., Hamann, A., Twardella, D. et al. (2008) Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. European Heart Journal, 29, 1307 1315. (Pubitemid 351768129)
7. Pilz, S., Mangge, H., Wellnitz, B. et al. (2006) Adiponectin and mortality in patients undergoing coronary angiography. Journal of Clinical Endocrinology and Metabolism, 91, 4277 4286. (Pubitemid 44833399)
8. Schulze, M.B., Shai, I., Rimm, E.B. et al. (2005) Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes, 54, 534 539.
9. Lim, S., Koo, B.K., Cho, S.W. et al. (2008) Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study. Atherosclerosis, 196, 398 404.
10. Basu, R., Pajvani, U.B., Rizza, R.A. et al. (2007) Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes, 56, 2174 2177. (Pubitemid 47195840)
11. Kobayashi, H., Ouchi, N., Kihara, S. et al. (2004) Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circulation Research, 94, e27 31.
12. Colhoun, H.M., Betteridge, D.J., Durrington, P.N. et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 364, 685 696. (Pubitemid 39140624)
13. Endres, M. (2006) Statins: potential new indications in inflammatory conditions. Atherosclerosis Supplement, 7, 31 35.
14. Saito, S., Fujiwara, T., Matsunaga, T. et al. (2008) Increased Adiponectin synthesis in the visceral adipose tissue in men with coronary artery disease treated with pravastatin: A role of the attenuation of oxidative stress. Atherosclerosis, 199, 378 383.
15. Takagi, T., Matsuda, M., Abe, M. et al. (2008) Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis, 196, 114 121.
16. Ando, H., Sugimoto, K.I., Yanagihara, H. et al. (2008) Effects of atorvastatin and paravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolemic patients. Clinical and Experimental Pharmacology and Physiology, 35, 1012 1017.
17. Blanco-Colio, L.M., Martín-Ventura, J.L., Gómez-Guerrero, C. et al. (2008) Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. European Journal of Pharmacology, 586, 259 265.
18. Schneider, J.G., von Eynatten, M., Parhofer, K.G. et al. (2004) Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis, 175, 325 331. (Pubitemid 38942913)
19. von Eynatten, M., Schneider, J.G., Hadziselimovic, S. et al. (2005) Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes. Diabetes Care, 28, 754 755. (Pubitemid 40315347)
20. Bobbert, T., Rochlitz, H., Wegewitz, U. et al. (2005) Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes, 54, 2712 2719. (Pubitemid 41233594)
21. Westphal, S. Luley, C. (2008) Preferential increase in high molecular weight adiponectin after niacin. Atherosclerosis, 198, 179 183.
22. Zamboni, M., Di Francesco, V., Garbin, U. et al. (2007) Adiponectin gene expression and adipocyte NF-κB transcriptional activity in elderly overweight and obese women: inter-relationships with fat distribution, hs-CRP, leptin and insulin resistance. International Journal of Obesity, 31, 1104 1109. (Pubitemid 46987770)
23. van Harmelen, V., Skurk, T., Röhrig, K. et al. (2003) HMG-CoA reductase inhibitor cerivastatin inhibits interleukin-6 expression and secretion in human adipocytes. Hormone and Metabolic Research, 35, 466 470. (Pubitemid 37204562)
24. Delerive, P., De Bosscher, K., Besnard, S. et al. (1999) Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. Journal of Biological Chemistry, 274, 32048 32054.
25. Bodles, A.M., Banga, A., Rasouli, N. et al. (2006) Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. American Journal of Physiology Endocrinology and Metabolism, 291, E1100 E1105.
26. Fruebis, J., Tsao, T.S., Javorschi, S. et al. (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proceedings of the National Academy of Science USA, 98, 2005 2010. (Pubitemid 32165613)